> ## Content Index
> Fetch the complete content index at: https://nexi.fund/llms.txt
> Use this file to discover other available public pages before exploring further.

# Caplight Raises 6M as Private Biotech Secondary Market Infrastructure Matures
- URL: https://nexi.fund/caplight-biotech-secondary-market-2026/
- Published: 2026-07-18T15:30:45.000Z
- Updated: 2026-07-18T15:30:45.000Z
- Description: Caplight $16M Series A led by BlackRock and Fin Capital signals institutional-grade infrastructure for a $12T private market asset class.
- Author: Nexi.fund Labs
- Tags: Biotech & Health, #mode-1, #hook-number, #track-F

A BlackRock-led **$16 million** Series A for a company most people have never heard of. That is not a large round by 2026 standards. Not when OpenAI raises in the billions. But Caplight is not building a model. It is building market infrastructure for a **$12 trillion** asset class that outgrew its trading rails three years ago.

🎯

**Venture capital tripled into a $12+ trillion asset class in three years, and the infrastructure to trade, price, and research private companies is only now catching up.**  
  
Caplight has assembled **$300+ billion** in proprietary secondary transaction data and **$5+ billion** in daily live order flow, giving institutional investors a single platform to price pre-IPO equity, discover deal-flow, and execute secondary trades.  
  
The round, co-led by BlackRock and Fin Capital with UBS as a strategic investor, marks the moment private secondary market infrastructure stopped being experimental and became institutional. 

The venture capital industry has done something unusual over the last three years: it tripled in size without the market infrastructure to support that growth. The number of private companies with venture backing now exceeds 50,000 globally. The platform tracks every one of them: funding history, cap table data, investor profiles, secondary pricing, employee growth, product launches, and customer wins. The scale is 100,000 company and investor profiles, $4 trillion in tracked funding rounds, and customers who collectively manage over $52 trillion in assets.

$300B+ proprietary secondary data ↑ 10× since 2022 

#### Caplight's Secondary Market Data Volume

$5+ billion in daily live transaction flow across pre-IPO companies. Platform covers 50,000+ private companies with 14 signal types. · *Caplight, June 2026*

## What secondary infrastructure actually means

The secondary market for private company shares has existed for years: broker desks, matchbooks, SPVs, one-off bilateral deals. But it was fragmented, opaque, and expensive. A fund manager wanting to price a basket of pre-IPO tech companies had to call three brokers, wait for indications, and triangulate. Pricing data was siloed inside the few firms that could afford dedicated secondary teams.

It changes that by doing three things on one platform. First, it aggregates **pricing data** from funding rounds, closed secondary trades, live bids and offers, and fund marks, then runs it through a patented model (US Patent No. 12,243,130) to produce daily price points on actively traded names. Second, it surfaces **deal flow**: $5+ billion in live buy and sell indications from the largest network of institutional brokers and counterparties. Third, it provides **company intelligence**: 14 signal types across funding events, talent moves, product launches, and commercial wins, refreshed continuously.

The result is the closest thing private markets have to a Bloomberg terminal: an institutional-grade data and execution layer for an asset class that, until now, operated on handshake economics.

## Why now: three forces converged

Three structural shifts explain why the Series A matters beyond the company itself.

**The IPO window stayed narrow.** After the 2021 peak, public listings never fully reopened. Private companies that would have gone public in a normal cycle remained private longer. The 28 companies on Limen Markets' platform have a median age of eleven years. More private companies means more shares that need to change hands before a liquidity event.

**Limited partners want liquidity.** Pension funds and endowments that committed capital to venture funds in 2019–2021 are now sitting on mark-to-paper returns they cannot realize. Secondary sales — selling fund stakes or direct positions in high-conviction private names — have become the primary release valve. The company's own data shows that 44% of company-approved secondary volume in 2025 came from funds, up from 9% in 2022\. That is $1 billion in fund-led volume, a 10× jump, with two-thirds arriving in institutional-sized blocks above $10 million.

**Taboo turned to standard practice.** A VC fund selling on the secondary market was once a signal of distress. That stigma has evaporated. Funds now routinely manage portfolios through partial secondary sales, and the question has shifted from "should we sell?" to "how much, and at what price?"

📊

**The institutionalization of private secondary markets**  
  
Fund share of secondary volume: **9%** (2022) → **44%** (2025)  
Fund-led volume: **$100M** → **$1B** (10× in 3 years)  
Blocks ≥ $10M: two-thirds of all fund-led trades  
*Source: Caplight Secondary Market Update, April 2026* 

## Biotech secondary markets: the missing link

Of the 491 biotech and pharma companies tracked on competing platform Forge Global, most are pre-revenue, pre-profit, and years from a liquidity event. Biotech has the longest time-to-exit of any venture-backed sector. A drug candidate takes a decade from IND filing to approval, with clinical trial failure rates above 90% at Phase 1\. That timeline creates a structural secondary market demand that other sectors do not share.

It tracks dozens of biotech companies on its platform: ParcelBio ($14M seed), Converge Bio ($25M Series A), Leman Biotech ($28M Series A extension), and others, providing the same pricing and deal-flow infrastructure that institutional investors use for SpaceX, OpenAI, and Anduril. For a sector where information asymmetry between insiders and outside investors is extreme, having transparent secondary pricing changes the due diligence equation.

It also serves a different buyer profile for biotech. Family offices writing $1M–$25M checks are now the largest buyer cohort in late-stage secondaries overall, but for biotech specifically, crossover funds and dedicated secondary funds (Industry Ventures, StepStone, Hamilton Lane) dominate because the science requires specialist analysis that most family offices cannot sustain in-house. The company's platform narrows this gap by surfacing the same 14 signal types for biotech companies — funding rounds, senior hires, clinical trial milestones, patent filings — that it tracks for tech companies, making sector-specific due diligence more accessible to a broader investor base.

## What this means for institutional allocators

The Series A signals a broader thesis: private secondary market infrastructure will become a standard part of institutional portfolio management, the way Bloomberg terminals, FactSet, and Aladdin became standard for public markets.

BlackRock's participation is the signal to watch. The world's largest asset manager does not invest $16 million in a secondary data startup for the financial return. It invests to integrate Caplight's data into Aladdin, its portfolio management platform, and to give its clients visibility into a $12 trillion asset class that most of them currently price by rumor. The strategic partnership with UBS, which joined the round as both investor and partner, reinforces this: investment banks need secondary market data to serve their private-wealth clients who increasingly want pre-IPO exposure.

The immediate implications for allocators are concrete. Better pricing data reduces the bid-ask spread that funds pay when buying or selling private company shares. Real-time signal tracking replaces the quarterly email from a GP with continuous updates on portfolio company health. And a centralized secondary marketplace means funds can execute trades in days rather than months, matching the cadence of institutional portfolio rebalancing rather than the ad-hoc rhythm of the broker-phone era.

### What happens to private market infrastructure a year from now?

🔮

**Within 18 months, the top 50 institutional allocators will subscribe to at least one private secondary data platform, either Caplight or a competitor, as standard infrastructure, not experimental overlay.**  
  
Probability: 65%. The same institutional demand curve that made Bloomberg terminals mandatory in the 1990s is repeating for private markets, compressed into a faster cycle because the asset class is already valued at $12 trillion and growing. 

#### ✅ Arguments for

BlackRock's Aladdin integration creates an immediate distribution channel to 50,000+ institutional clients.  
Its patent-protected pricing model gives it a data-moat advantage over new entrants.  
The $5B+ daily order flow is already sufficient liquidity for most institutional block sizes.  
  
**Confirmation criteria:** A second top-10 asset manager takes a strategic stake in the company or a direct competitor within 12 months. 

#### ❌ Arguments against

Private secondary trading volumes are still a fraction of public markets. The company captured $3.5B in all of 2025 versus $50B+ daily on the NYSE alone. The infrastructure build-out may outrun actual trading demand.  
Existing brokers and placement agents have strong incumbent relationships that platform-based disintermediation has not yet cracked.  
Regulatory uncertainty around private securities trading could slow adoption.  
  
**Disconfirmation criteria:** Its daily order flow drops below $2B or a major competitor exits the space within 18 months. 

### Development scenarios

#### 🟢 Optimistic scenario (30%)

BlackRock and UBS begin actively routing client flows through its marketplace. Secondary trading volumes double within 12 months. The company becomes the default pricing source for pre-IPO biotech and tech companies, capturing 30%+ market share in institutional secondary execution.  
  
**Implications:** Pre-IPO price discovery becomes as transparent as public-market price discovery for the most actively traded names, narrowing the liquidity premium that private markets have historically commanded. 

#### 🟡 Base-case scenario (50%)

It continues to grow its data business at 40–60% YoY, adding new institutional clients and expanding its company coverage. Secondary trading volumes grow steadily but not exponentially, constrained by the fundamental illiquidity of private company shares. The platform becomes a standard reference tool for secondary specialists but does not achieve the universal adoption of a Bloomberg terminal.  
  
**Implications:** Private market transparency improves meaningfully but remains a specialist domain. Family offices and small funds still rely on broker relationships for execution, while large asset managers use the platform for pricing and screening. 

#### 🔴 Pessimistic scenario (20%)

A broader market downturn compresses private company valuations and dries up secondary trading volumes. IPO windows reopen, drawing liquidity away from the secondary market back to primary listings. Its institutional clients delay or cancel platform commitments as trading desks shrink headcount.  
  
**Implications:** The private secondary infrastructure build-out stalls, and the market reverts to the broker-phone model until the next cycle. The company survives but pivots to a narrower data-licensing business rather than the full execution platform. 

📊

**Key signals to track**  
  
Its daily order flow crosses $8B, indicating institutional adoption accelerating beyond early adopter stage  
A second major bank (Goldman Sachs, Morgan Stanley) takes a strategic position in a competitor or partnership, signaling the infrastructure play is real  
SEC issues guidance on private secondary trading platforms, providing regulatory clarity or constraint  
Its biotech secondary volume exceeds $500M annually, confirming the biotech-specific thesis 

[ Caplight Raises $16M Series A led by BlackRock and Fin Capital Full press release detailing Caplight's $16M Series A led by BlackRock and Fin Capital, with strategic participation from UBS and platform metrics. The AI Journal / PR Newswire ](https://aijourn.com/caplight-raises-16m-series-a-led-by-blackrock-and-fin-capital-to-power-the-next-era-of-private-markets/?ref=nexi.fund) 

Primary source on the funding round and quoted rationale from BlackRock and Caplight management.

[ Caplight Raises $16M Series A led by BlackRock and Fin Capital Official press release detailing Caplight's platform metrics: $300B+ in secondary data, $5B+ daily flow, 100K profiles, $52T in client AUM. PR Newswire / Yahoo Finance ](https://finance.yahoo.com/markets/stocks/articles/caplight-raises-16m-series-led-101500917.html?ref=nexi.fund) 

Company's own data figures used throughout this analysis.

[ The pre-IPO secondary market in 2026: a complete map Limen Markets provides a detailed overview of the 2026 secondary market structure, buyer profiles, and seller dynamics. Limen Markets ](https://limenmarkets.com/resources/pre-ipo-market-2026?ref=nexi.fund) 

Market structure context for buyer and seller dynamics in private secondaries.